Home » USA Broker Ratings » Alnylam Pharmaceuticals, Inc. – Consenus Indicates Potential 14.1% Upside

Alnylam Pharmaceuticals, Inc. – Consenus Indicates Potential 14.1% Upside

Alnylam Pharmaceuticals, Inc. with ticker code (ALNY) have now 20 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 190 and 62 with a mean TP of 134.65. Given that the stocks previous close was at 118.06 this would indicate that there is a potential upside of 14.1%. The 50 day MA is 118.07 and the 200 moving average now moves to 90.53. The market cap for the company is $13,730m. You can visit the company’s website by visiting: http://www.alnylam.com

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company’s pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. It provides ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. The company’s development programs include Vutrisiran, an investigational RNAi therapeutic targeting transthyretin that is in Phase III trials for the treatment of transthyretin-mediated amyloidosis; Givosiran that is in Phase III trials to treat acute hepatic porphyrias; and Lumasiran, an investigational RNAi therapeutic, which is in Phase III clinical trials for glycolate oxidase to treat primary hyperoxaluria type 1. It is also developing Inclisiran, an investigational RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9 that is in Phase III clinical trials for the treatment of hypercholesterolemia; and Fitusiran, an investigational RNAi therapeutic that is in Phase III clinical trials for treating hemophilia A and B with or without inhibitors. In addition, the company engages in the development of Cemdisiran for complement-mediated diseases; ALN-AAT02 to treat alpha-1 anti-trypsin deficiency-associated liver disease; ALN-HBV02 for treating chronic hepatitis B virus infection; and other earlier-stage programs. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Join us on our new LinkedIn page

Follow us on LinkedIn